Wenger Vieli advises NLS Pharmaceutics on a private placement

Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m.

NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders. NLS intends to use the net proceeds from the offering to fund the ongoing development of its lead product, Quilience®for the treatment of narcolepsy, to support business development and licensing activities, and for general corporate purposes.

The Wenger Vieli team was led by partner Pascal Honold (m&a /vc/pe, pictured) and included Kevin Vangehr (associate, m&a / vc/pe), Alessa Waibel (associate, financial services) and Andrea Christen (associate, m&a / vc/pe).

Wenger Vieli advises NLS Pharmaceutics on a private placement



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram